Teva Gets Exclusivity For Generic Kytril; FDA Still Worries About Racing, Parking
Executive Summary
In granting Teva 180-day marketing exclusivity for its generic formulation of Roche's antinausea drug Kytril (granisetron), FDA has laid out initial ground rules for determining when ANDA holders forfeit exclusivity
You may also be interested in...
ANDA Filing Free-For-All? Matrix's Stay In Kaletra Case Could Remove Risks Of Submitting Early Dual Certification Generic Drug Applications
Matrix's ability to win a stay of litigation over Kaletra patents - and thus avoid a potential forfeit of its generic exclusivity - suggests a possible strategy for other early ANDA filers
ANDA Filing Free-For-All? Matrix's Stay In Kaletra Case Could Remove Risks Of Submitting Early Dual Certification Generic Drug Applications
Matrix's ability to win a stay of litigation over Kaletra patents - and thus avoid a potential forfeit of its generic exclusivity - suggests a possible strategy for other early ANDA filers
ANDA Reviews: Inspector General Weighs In, But Progress Depends On Congress
A report by the HHS Office of Inspector General on FDA's review process for generic drugs illuminates the challenges the agency faces, but reaction to the report underscores the impression that complete resolution of the issue will require Congressional intervention